Welcome to our dedicated page for Radius Health news (Ticker: RDUS), a resource for investors and traders seeking the latest updates and insights on Radius Health stock.
Radius Recycling, Inc. generated company news around recycled metals processing, nonferrous and ferrous market conditions, finished steel operations, earnings releases, and operating initiatives in metal recovery and recycling services. Coverage also included governance changes and capital-structure matters tied to material agreements and shareholder actions.
In July 2025, Radius Recycling completed a merger and became a wholly owned subsidiary of Toyota Tsusho America, Inc. Subsequent RDUS-related developments center on the company's corporate-status transition, delisting and deregistration steps, and historical public-company disclosures.
Radius Health, Inc. (Nasdaq: RDUS) will release its second quarter financial results on August 5, 2021, and host a conference call at 8:30 a.m. ET to discuss the results and provide updates. Investors can join the conference at 1 (800) 446-1671 or 1 (847) 413-3362 using conference ID 50202646. A replay will be available later that day. Radius is focused on addressing unmet medical needs in endocrinology and has a pipeline including TYMLOS® and investigational drugs for osteoporosis and breast cancer.
Radius Health, Inc. (NASDAQ: RDUS) reported a modest increase in new patients for TYMLOS, with approximately 1,650 new patients added in April, reflecting a 1% growth compared to the previous four months. The FDA provided guidance on generic peptide approval, indicating challenges for future generic versions of abaloparatide. The company anticipates pivotal trials for RAD011 addressing Prader-Willi Syndrome and continued technical development for the abaloparatide depot formulation in the second half of 2021.
Radius Health reported Q1 2021 total net revenue of $56 million, a 17% increase from $48 million in Q1 2020. However, TYMLOS U.S. product revenue declined 6% year-over-year to $45 million. The company's adjusted EBITDA improved to ($5 million) from ($26 million) in the prior year. The net loss decreased to $15.7 million or $0.34 per share, compared to $37.7 million or $0.81 per share in Q1 2020. Humana has added TYMLOS to its Medicare Advantage Plans, expanding coverage for ~5 million beneficiaries.
Radius Health, Inc. (Nasdaq: RDUS) reported a 14% growth in new U.S. TYMLOS patients in Q1 2021 compared to Q4 2020. However, the net revenue for Q1 was impacted by seasonality and distribution channel destocking. Positive indications for future growth are evident with strong patient additions in April. The company is on track for multiple pivotal studies and successful outcomes from recent human factor studies, paving the way for regulatory submissions. A Type C FDA meeting for RAD011 is scheduled for June 2021, examining additional orphan indications.
Radius Health (Nasdaq: RDUS) will release its first quarter financial results on May 7, 2021, at 8:30 a.m. ET, followed by a conference call and live audio webcast. The call will discuss the financial outcomes and provide company updates. A replay will be available later that day and archived for ninety days. Radius focuses on unmet medical needs in endocrinology, with its lead product TYMLOS® approved for postmenopausal women at high risk for fracture. The company has multiple investigational drugs in its pipeline, enhancing potential future growth.
Radius Health's partner, Teijin Pharma, achieved regulatory success in Japan with the approval of Ostabaro® for osteoporosis treatment in high-risk patients. This approval positions Japan as the largest anabolic market globally, generating a $10 million milestone for Radius. The company plans to re-file abaloparatide in the EU by Q4 2021 after a thorough consultation process. Additionally, TYMLOS® is experiencing new patient growth, with an estimated 4,742 new patients in Q1 2021, up from 4,495 in Q4 2020, while reaffirming a $250 million revenue target for 2021.
Radius Health, Inc. (RDUS) announced a financial transaction involving the repurchase of $112.2 million in 3.00% convertible notes due September 1, 2024, eliminating potential dilution of about 2.3 million shares. The move is expected to enhance liquidity by approximately $14.2 million and improve the company’s debt structure. Radius reaffirmed its 2021 financial guidance, projecting $10 million of positive EBITDA. The transaction, supported by MidCap Financial, reflects the company's improved financial strength and aims to optimize its capital structure.
Radius Health reported Q4 2020 net sales of TYMLOS at $60 million, an 8% increase year-over-year, contributing to a full-year revenue of $208 million, up 20% from 2019. New patient starts rose by 26% in Q4 compared to Q3. The company recorded a net loss of $21.4 million in Q4 2020, improving from a loss of $24.7 million in Q4 2019. R&D expenses increased to $36.4 million, driven by RAD011 and abaloparatide programs. Despite a cash balance of approximately $115 million at year-end, Radius reduced its workforce by over 25% to enhance operational efficiency.
BOSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Radius Health announced it will present a corporate update at the 10th Annual SVB Leerink Global Healthcare Conference at 10:40 a.m. ET on February 25, 2021. The presentation will be accessible via a live webcast on the Company's website, with a replay available for 90 days afterwards.
Radius is focused on developing endocrine therapeutics, with its lead product TYMLOS® approved for treating high-risk postmenopausal women with osteoporosis. The company has additional investigational drugs targeting osteoporosis and hormone-receptor positive breast cancer.
Radius Health (Nasdaq: RDUS) will announce its fourth quarter financial results on February 25, 2021, followed by a conference call at 8:30 a.m. ET. The call will provide insights into the company’s performance and future prospects. Investors can listen to the live audio webcast on the company’s website, and a replay will be available later that day. Radius focuses on innovative endocrine therapeutics, with its lead product TYMLOS (abaloparatide) approved for osteoporosis treatment. The company is also advancing several investigational drugs in its pipeline.